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Abstract
Most persons with chronic hepatitis C virus (HCV) infection in the United States are undiagnosed 
or linked to care. We describe a program for the management of Alaska Native patients infection 
utilizing a computerized registry and statewide liver clinics resulting in higher linkage to care 
(86%) than national estimates (~25%).
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Chronic hepatitis C virus (HCV) infection is a significant worldwide etiology of cirrhosis, 
liver failure, and hepatocellular carcinoma (HCC). In the United States, an estimated 3.5 
million persons have HCV infection. Viral hepatitis is now responsible for more deaths in 
the United States than human immunodeficiency virus [1]. A recent meta-analysis estimated 
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that only 50% of persons with HCV infection were aware of their diagnosis; of those, 43% 
of had access to care and only 25% were tested for HCV RNA, the confirmatory test for 
HCV infection [2]. Despite the development of highly effective HCV direct antiviral agents 
(DAAs) resulting in greater than 90% sustained viral response (SVR), the majority of 
persons infected with HCV are not diagnosed or linked to care.
The Alaska Native Tribal Health Consortium (ANTHC) Liver Disease and Hepatitis 
Program (LDHP) has been involved in the care of Alaska Native/American Indian (AN/AI) 
persons with HCV infection since 1994. The LDHP focuses HCV infection screening on 
high-risk individuals and has a program for screening Baby Boomers (born 1945–1965). All 
persons positive for HCV serology are entered into a statewide HCV registry used for patient 
tracking and management. This paper examines the cascade of care—defined as the 
continuum from screening, diagnosis, linkage to care, evaluation for therapy, and treatment 
of HCV infection—for AN/AI persons with chronic HCV infection from January 2014 
through December 2017.
METHODS
The ANTHC coordinates healthcare within the Alaska Tribal Health System (ATHS) for an 
estimated 160 000 AN/AI people throughout the state of Alaska, with more than 50% living 
in rural communities [3]. Primary care is provided in remote communities by community 
health aide practitioners [4]. In larger communities, both primary and secondary care is 
available at regional hospitals and clinics staffed by physicians and midlevel providers. In 
Anchorage, the Southcentral Foundation and the Alaska Native Medical Center (ANMC) 
provide primary and tertiary care, respectively. Further details of the population and 
healthcare delivery system have previously been described [3]. Electronic health records are 
used throughout ATHS facilities.
The Liver Disease and Hepatitis Program Hepatitis C Virus Registry
The LDHP maintains a computerized registry of all patients who tested positive for HCV 
antibody (anti-HCV), which includes extensive laboratory, clinical, and demographic data 
used primarily for management of AN/AI persons with chronic HCV infection. All patients 
in the HCV registry receive a letter every 6 months asking them to attend their local clinic 
for liver function tests. Those patients with evidence of cirrhosis receive a second letter, at 6-
month intervals, recommending a liver ultrasound for HCC surveillance. Each clinic, 
provider, and regional facility receive a list of patients to be tested in their respective areas. 
Testing for anti-HCV is performed at the ANMC, and positive serum samples are reflex 
tested for HCV RNA. Pertinent laboratory tests, including liver function tests and complete 
blood count, are uploaded biweekly into the Alaska Native Hepatitis C (AK-HepC) Registry 
database. The LDHP also conducts regularly scheduled hepatology field clinics at 10 ATHS 
hospitals throughout Alaska.
From the mid-1990s, all eligible patients have been offered Food and Drug Administration 
(FDA)–approved drugs for HCV infection treatment based on guidelines from the American 
Association for the Study of Liver Diseases/Infectious Diseases Society of America [5]. 
Direct antiviral agent treatment is provided regardless of liver fibrosis stage or medical 
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coverage. All currently licensed DAA medications are made available as soon as they are 
FDA approved. For rural communities, LDHP uses telephone consults, telemedicine, virtual 
(Vidyo®) clinics, tele-radiography, and other means to support local providers in caring for 
patients with HCV infection.
In addition, a nurse/patient navigator aids compliance by determining patient eligibility, 
providing patient education regarding HCV infection and treatment, and aiding any medical 
coverage needs. The patient navigator tracks patient progress during treatment and reminds 
patients of appointments with frequent phone calls and text messages. Since 1995, the 
LDHP has reported the clinical outcomes of chronic HCV infection [4, 6, 7].
Cascade of Care
The cascade of care takes a population perspective of illness by following the patient 
pathway through screening, diagnosis, testing, linkage to care, and treatment. We tracked the 
following numbers: (1) persons tested for HCV infection, (2) persons with a positive anti-
HCV test, (3) persons with chronic HCV infection as determined by the presence of HCV 
RNA, (4) persons linked to a knowledgeable provider, (5) persons who meet eligibility for 
treatment, and (6) persons who have received antiviral therapy (Figure 1).
We characterized linkage to care as the proportion of persons who visited with a primary 
care provider or liver specialist for HCV laboratory and treatment evaluation or received a 
letter reminding them to make an appointment to see a provider for HCV infection. 
Treatment eligibility is determined by whether patients keep at least 2 consecutive clinic 
appointments: the first to explain the treatment regimen and draw serum samples for testing; 
the second to review laboratory results and start DAA treatment. The Alaska Area and 
Centers for Disease Control and Prevention Institutional Review Boards as well as the 
regional Tribal health organizational review boards in Alaska all approved the study. This 
manuscript has been reviewed by the Alaska Native Tribal Health Consortium and 
Southcentral Foundation tribal review boards.
RESULTS
We analyzed persons who visited the LHDP liver clinic for an appointment or blood draw 
between 1 January 2014 and March 2017. We identified 3443 persons with an anti-HCV 
positive test in our database; 97% had HCV RNA testing performed (Figure 1). As of 31 
December 2017, 660 persons had died, 1058 (38%) were HCV RNA negative or had 
resolved their HCV infection within 1 year, 46 had no confirmation test performed, and 98 
had been cured with interferon-based therapy. This left 1581 persons remaining who were 
HCV RNA positive for 12 months or longer. Of the 1581 persons identified with chronic 
HCV infection, 125 (8%) were lost to follow-up. Of the remaining 1358 persons linked to 
care, 999 (74%) had been evaluated for DAA antiviral therapy, and the 359 patients who had 
not been evaluated had been sent repeated letters requesting that they make an appointment 
for treatment. Of the 999 evaluated for treatment, 872 (87%) persons were deemed eligible 
for treatment and 127 (13%) were not. As of 31 December 2017, of the 872 persons deemed 
treatment ready, 669 (77%) have started therapy, leaving 203 (25%) who were awaiting 
treatment. Sustained viral response was achieved in 96% of those who completed therapy.
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DISCUSSION
Our program has achieved many successful elements in our ultimate goal for elimination of 
HCV for the AN/AI people. These elements include high percentages of persons with HCV 
RNA testing (97%), linkage to care (>80%), and DAA-based treatment eligibility 
determination (>85%).
Our program faces unique logistics in delivery of care, as many persons with HCV live in 
rural communities throughout Alaska, some without road access to medical facilities. 
Success requires a great deal of coordinated care with many providers, including community 
health aide practitioners. Our program can act as a model for regions of the world where 
many persons with chronic HCV infection live in both urban and remote communities. The 
epidemiology of HCV infection in the AI/AN population is similar to that of the US 
population, but AI/AN persons with chronic HCV infections have higher rates of liver 
failure, HCC, and liver-related death [3, 4]
With the advent of high efficacy and minimal side-effect DAA-based therapies for HCV 
infection, it is imperative to link untreated persons to care to prevent long-term liver disease 
complications. Direct antiviral agent drug costs are decreasing as a treatment barrier. As 
shown during interferon treatment regiments, curing HCV infection in persons with cirrhosis 
reduces the subsequent risk of developing HCC by 70% and of liver failure by 90% [8]. Half 
of our persons infected with HCV achieving an SVR have advanced liver fibrosis (Metavir 
F3 and F4). Curing persons with no or mild fibrosis protects from future risk of adverse 
outcomes. Economically, HCV treatment will prove worthwhile in reducing medical costs 
associated with adverse outcomes.
Several reports about the cascade of care in major health care organizations have been 
published. Two programs with considerable government funding, one in the US Veterans 
Affairs healthcare system and the other in Australia, are on the way to eliminating HCV in 
these populations [9, 10]. However, in other North American populations, there is a deficit in 
screening high-risk populations for HCV infection and subsequent drop off in the 
proportions of HCV-positive persons undergoing an HCV RNA test (60%–70%), those who 
are referred to knowledgeable providers (34%–76%), and those who are treated (12%–34%) 
[11, 12]. The drop-off rate from testing anti-HCV positive results for HCV RNA in our 
cohort was only 3%.
Our goal is to treat all persons with HCV infection. Establishing strong case-management 
tools such as computerized registries and reminder systems for patients with HCV infection 
could also link persons infected with HCV to care and treatment programs, including in 
communities with practitioners with limited formal training. Cascade of care programs are 
moving systems, and periodic evaluation of the components are of value to ensure ongoing 
success in the management and care for persons with chronic HCV infection.
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Figure 1. 
Hepatitis C virus cascade of care for Alaska Native persons living in Alaska, 2014–2017. 
Abbreviations: HCV, hepatitis C virus; IFN, interferon.
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